Newcomer Catalio builds momentum with $381M biotech venture fund

Catalio’s new $381 million fund is the third for the three-year-old firm, pushing its assets under management to over $1 billion. Along the way, the venture newcomer has invested in 45 biopharma companies while managing to attract some of academia’s biggest names as scientific founders.

The close of Catalio Capital Management’s Catalio Nexus Fund III surpasses the firm’s initial target of $300 million and is nearly 4x the size of its $100 million predecessor...